Immunotherapy with chemo for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (adebrelimab) with or without another targeted drug (apatinib) to standard chemotherapy is more effective for advanced stomach cancer. It aims to shrink tumors and improve outcomes for people who haven't had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread.
- You have not had any chemotherapy, radiation, or immunotherapy for advanced stomach cancer before.
- Your overall health is good (ECOG score 0 or 1), meaning you can carry out daily activities without much trouble.
- Your blood counts, liver, and kidney function are within a certain range (your doctor can check this).
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This study tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or GEJ cancer that continued to grow after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (capecitabine and oxaliplatin) for people with stomach cancer or cancer where the stomach meets the esophagus. It aims to see if this combination is safe and effective for patients who have not had prior treatment for advanced disease.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.